Kim, Yungi

写真a

Affiliation

Faculty of Pharmacy 創薬研究センター (Shiba-Kyoritsu)

Position

Professor (Non-tenured)

Career 【 Display / hide

  • 2006.01
    -
    2011.07

    University of Michigan, Department of Pathology, Post-doctral fellow

  • 2011.07
    -
    2013.06

    筑波大学, 医学医療系, 助教

  • 2013.06
    -
    2015.06

    University of Michigan, Department of Pathology, Research Investigator

  • 2015.06
    -
    2016.07

    Vedanta Biosciences, Inc., Senior Scientist

  • 2016.08
    -
    2018.09

    慶應義塾大学, 薬学部生化学講座, 准教授

display all >>

Academic Degrees 【 Display / hide

  • 博士(薬学), 北里大学, 2005.03

Licenses and Qualifications 【 Display / hide

  • 薬剤師, 2000

 

Research Keywords 【 Display / hide

  • アレルギー

  • 感染免疫

  • 腸内細菌

  • 自然免疫

Research Themes 【 Display / hide

  • 腸内環境調節と炎症性疾患の制御に関する研究, 

    2016
    -
    Present

 

Books 【 Display / hide

  • ヒトマイクロバイオーム Vol.2 ~解析技術の進展とデータ駆動型・ターゲット機能型研究最前線~

    金 倫基,  (株)エヌティーエス, 2020.06

    Scope: 第2節 乳幼児の腸内細菌叢の特性

  • 腸内細菌叢を標的とした医薬品と保健機能食品の開発

    金 倫基, 技術情報協会, 2018.09

    Scope: 腸内細菌叢の創薬応用の研究開発の現状と可能性について

  • ヒトマイクロバイオーム研究最前線

    金 倫基渋谷 彰, (株)エヌ・ティー・エス, 2016.03

    Scope: 腸内細菌叢と喘息

Papers 【 Display / hide

  • Colonization of the Live Biotherapeutic Product VE303 in Healthy Volunteers and Associations with the Resident Microbiota and Metabolites

    Dsouza M., Menon R., Crossette E., Bhattarai S., Schneider J., Kim Y.G., Reddy S., Caballero S., Felix C., Cornacchione L., Hendrickson J., Watson A., Minot S., Greenfield N., Schopf L., Szabady R.,Patarroyo J., Smith W., Harrison P., Kuijper E., Kelly C., Olle B., Bobilev D., Bucci V., Roberts B., Faith J., Norman J.

    Cell Host Microbe (Cell Press)  30 ( 4 ) 583 - 598 2022.04

    Research paper (scientific journal), Joint Work, Accepted

  • Gut microbiota reinforce host antioxidant capacity via the generation of reactive sulfur species

    Uchiyama J., Akiyama M., Hase K., Kumagai Y., Kim Y.G.

    Cell Reports (Cell Reports)  38 ( 10 )  2022.03

     View Summary

    Gut microbiota act beyond the gastrointestinal tract to regulate the physiology of the host. However, their contribution to the antioxidant capacity of the host remains largely understudied. In this study, we observe that gut bacteria increase the steady-state plasma levels of high-antioxidant molecules, reactive sulfur species (RSS), such as hydrogen sulfide and cysteine persulfide (CysSSH), in the host. Moreover, gut bacteria utilize cystine as a substrate to enzymatically produce CysSSH. Administration of cystine to mice increases their plasma levels of RSS and suppresses the concanavalin-A-induced oxidative stress and liver damage in a gut-microbiota-dependent manner. We find that gut bacteria belonging to the Lachnospiraceae and Ruminococcaceae families have a high capacity to produce RSS, requiring pyridoxal 5′-phosphate for their enzymatic reactions. Collectively, our data demonstrate that gut microbiota enhance the antioxidant capacity of the host through the generation of RSS.

  • Potentiation of methylmercury toxicity by combined metal exposure: in vitro and in vivo models of a restricted metal exposome

    Akiyama M., Shinkai Y., Yamakawa H., Kim Y.G., Kumagai Y.

    Chemosphere Accepted 2022.03

    Research paper (scientific journal), Joint Work, Accepted

  • A Randomized Placebo-Controlled Trial of Combination Therapy With Post-triple-antibiotic-therapy Fecal Microbiota Transplantation and Alginate for Ulcerative Colitis: Protocol

    Ishikawa D., Zhang X., Nomura K., Seki N., Haraikawa M., Haga K., Shibuya T., Kim Y.G., Nagahara A.

    Frontiers in Medicine (Frontiers in Medicine)  9 2022.02

     View Summary

    Background: Fecal microbiota transplantation (FMT) has been widely performed for ulcerative colitis (UC) treatment at the clinical trial stage. Previous reports have used multiple FMT methods to enhance the colonization of healthy donor microbiota in the recipient's intestines. FMT following triple antibiotic therapy with amoxicillin, fosfomycin, and metronidazole (A-FMT) is not only effective but also requires only one FMT, which improves dysbiosis caused by reduced Bacteroidetes diversity in patients with UC. Alginate and its derivatives have the potential to induce the growth of intestinal bacteria including Bacteroides members and produce short-chain fatty acids (SCFAs), which are beneficial in regulating overactive autoimmunity. Our trial aims to investigate whether post-intervention with alginate, which can improve the intestinal environment, will enhance the therapeutic effect of A-FMT in UC and increase the long-term remission rate. Methods and Analysis: This trial is a double-blinded, randomized, placebo-controlled, parallel assignment trial. Patients with UC and fecal donation candidates will undergo strict screening before being involved in the trial. Eligible patients are randomly divided into two groups: one group will drink one bottle of alginate twice a day for 8 consecutive weeks after A-FMT, while the other group will take a placebo instead of the alginate drink. The primary endpoints are the changes in the Total Mayo Score at 8 weeks after study initiation and A-FMT from baseline. The secondary endpoint is the comparison of clinical features, microbiota, and metabolomic analysis before and after 8 weeks of study food intake. Changes at 6, 12, 18, and 24 months after A-FMT will be assessed. Finally, a subpopulation analysis of the relationship between patients and donors is an exploratory endpoint. Discussion: The FMT post-treatment used in this study is an oral alginate drink that is easily accepted by patients. If the regimen achieves the desired results, it can further improve the A-FMT regimen and provide evidence for clinical practice guidelines for UC. Clinical Trial Registration: https://jrct.niph.go.jp/latest-detail/jRCTs031200103, identifier: jRCTs031200103.

  • Specific adsorption of a β-lactam antibiotic: In vivo by an anion-exchange resin for protection of the intestinal microbiota

    Li S., Yakabe K., Zai K., Liu Y., Kishimura A., Hase K., Kim Y.G., Mori T., Katayama Y.

    Biomaterials Science (Biomaterials Science)  9 ( 21 ) 7219 - 7227 2021.11

    Research paper (scientific journal), Accepted,  ISSN  20474830

     View Summary

    The fraction of antibiotics that are excreted from the intestine during administration leads to disruption of commensal bacteria as well as resulting in dysbiosis and various diseases. To protect the gut microbiota during treatment with antibiotics, use of activated carbon (AC) has recently been reported as a method to adsorb antibiotics. However, the antibiotic adsorption by AC is nonspecific and may also result in the adsorption of essential biological molecules. In this work, we reported that an anion exchange resin (AER) has better specificity than AC for adsorbing the β-lactam antibiotic cefoperazone (CEF). Because CEF has a negatively charged carboxylate group and a conjugated system, the AER was used to adsorb CEF through electrostatic and π-π interactions. The AER was specific for CEF over biological molecules such as bile acids and vitamins in the intestine. The AER protected Escherichia coli from CEF in vitro. Furthermore, oral administration of the AER reduced the fecal free CEF concentration, and protected the gut microbiota from CEF-induced dysbiosis. This journal is

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • 腸内細菌叢の変動因子と生活習慣病

    山口 元輝, 秋山 雅博, 金 倫基

    機能性食品と薬理栄養 15 ( 4 ) 212 - 217 2022.02

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • 炎症性腸疾患をターゲットにした腸内細菌製剤の開発と現状

    矢加部 恭輔, 金 倫基

    Medical Science Digest (ニューサイエンス社)  47 ( 11 ) 6 - 10 2021.10

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • 腸内環境を変動させる因子

    金 倫基

    腸内細菌叢生態学 (実験医学)  38 ( 18 ) 3047 - 3052 2020.10

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Single Work

  • 腸内細菌叢を標的とした医薬品開発

    金 倫基

    実験医学別冊もっとよくわかる!腸内細菌叢 健康と疾患を司る“もう1つの臓器” (羊土社)     118 - 128 2020.09

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Single Work

  • 腸内細菌叢をターゲットにした創薬開発と課題

    金 倫基

    CARDIAC PRACTICE (メディカルレビュー社)  29 ( 4 ) 299 - 302 2019.02

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Single Work

display all >>

Presentations 【 Display / hide

  • 腸内環境制御によるサクセスフルエイジングの実現

    金 倫基

    第2回PAC国際シンポジウム, 

    2021.11

    Oral presentation (invited, special), プロダクティブ・エイジング コンソーシアム(PAC)

  • 腸内細菌の創薬応用

    金 倫基

    腸内デザイン学会 腸内環境をデザインする~新たな「腸内細菌叢学」を目指して~, 

    2020.11

    Symposium, workshop panel (nominated)

  • 抗肥満作用を発揮する腸内細菌関連代謝物の探索

    金 倫基

    第20回日本抗加齢医学会総会 腸内細菌の臨床応用 ―便移植からポストバイオティクスまで, 

    2020.09

    Oral presentation (invited, special)

  • 抗肥満作用を発揮する腸内細菌由来代謝物の探索

    金 倫基

    第32回微生物シンポジウム, 

    2020.09

    Symposium, workshop panel (nominated)

  • 腸内細菌と肥満

    金 倫基

    第64回日本薬学会関東支部大会 シンポジウムS5 宿主防御機構の新しい視点, 

    2020.09

    Symposium, workshop panel (nominated)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 炎症性腸疾患における腸内細菌病因説の検証

    2020.07
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Challenging Research (Exploratory), Principal investigator

  • Identification of microbiota-associated metabolite which protects against

    2020.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

  • 腸内細菌叢の成熟に伴う腸管病原菌に対する感染抵抗性獲得機構

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (A), Principal investigator

 

Courses Taught 【 Display / hide

  • PATHOBIOCHEMISTRY

    2022

  • INTRODUCTION TO THE PHARMACEUTICAL SCIENCES

    2022

  • PATHOBIOCHEMISTRY

    2021

  • INTRODUCTION TO THE PHARMACEUTICAL SCIENCES

    2021

  • PATHOBIOCHEMISTRY

    2020

display all >>